TB Archives – Page 37 of 49 – Treatment Action Group

Advancing Research, Securing Access

April 5, 2013
Chad Cipiti

By Mark Harrington Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and…

TAGline Spring 2013

April 5, 2013
Chad Cipiti

Advancing Research, Securing Access: Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and two of its insidious comorbidities, viral hepatitis and tuberculosis. Many of these challenges are inextricably intertwined, as we highlight in this issue focusing on specific clinical research and treatment-access hurdles threatening progress for all three diseases.

Children with Drug-Resistant Tuberculosis Require Urgent Attention

March 21, 2013
Chad Cipiti

Treatment Action Group (TAG), in partnership with the Sentinel Project on Pediatric Drug-Resistant Tuberculosis (Sentinel Project) released today We Can Heal: Prevention, Diagnosis, Treatment, Care and Support: Addressing Drug-Resistant Tuberculosis in Children. This collection, released in anticipation of World TB Day on March 24, calls for urgent attention to the global problem of pediatric drug-resistant tuberculosis (DR-TB).

We Can Heal: Prevention, Diagnosis, Treatment, Care, and Support: Addressing Drug-Resistant Tuberculosis in Children

March 20, 2013
Chad Cipiti

Prevention, Diagnosis, Treatment, Care, and Support: Addressing Drug-Resistant Tuberculosis in Children March 21, 2013 TB in a child is considered a sentinel health event as it signals recent transmission of tuberculosis (TB), which is preventable and curable. A child infected…

TAG Welcomes the FDA Approval of the First New Drug for TB in 40 Years

January 29, 2013
Chad Cipiti

by Erica Lessem December 28, 2012, was a historic day for the one million people around the world with strains of tuberculosis (TB) that are particularly difficult to treat. For the first time in forty years, the United States Food…

TB Zeroes Campaign Achieves Big Win

January 29, 2013
Chad Cipiti

by Erica Lessem The world has recently called for zero new TB deaths, infections, and suffering, and that voice has been heard. Treatment Action Group (TAG), along with other activists, researchers, clinicians, implementers, policy makers, and foundation and government staff…

TAGline Winter 2013

January 29, 2013
Chad Cipiti

Grief Is a Sword: A Eulogy for Spencer Cox; A Global Plan to End AIDS Everywhere but at Home ; On the Edge: Uncertainty Grows over HIV Budgets; Data Deluge at AASLD; Beyond ARVs: Advocacy for Non-AIDS Disease Management; TB Zeroes Campaign Achieves Big Win; TAG Welcomes the FDA Approval of the First New Drug for TB in 40 Years; Help Support Inclusion of Pegylated Interferon on the World Health Organization’s Essential Medicines List; Guide to Clinical Trials for People with Hepatitis C.

Treatment Action Group Lauds FDA Approval of First New Tuberculosis Drug in Half a Century

December 31, 2012
Chad Cipiti

Treatment Action Group (TAG) applauds the accelerated approval today of bedaquiline, the first new approved drug to treat tuberculosis (TB) in over forty years, by the U.S. Food and Drug Administration (FDA). The drug has the potential to improve the treatment for multi-drug resistant (MDR) TB, a particularly deadly and hard to treat form of TB that affects over a million people worldwide, and from which only about half of patients who are treated recover.

2012 TAG Update

December 11, 2012
Chad Cipiti

TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.

Statement on Bedaquiline to the FDA

November 28, 2012
Chad Cipiti

Statement of Mark Harrington, Executive Director, Treatment Action Group to the FDA Anti-Infective Drugs Advisory Committee (AIDAC) Hearing on the Use of Bedaquiline (TMC207) for Treatment of Multidrug-Resistant (MDR) Tuberculosis (TB)